PIK3CA Gene Mutation Analysis (Therascreen PIK3CA)
The PIK3CA gene is located on the long (q) arm of chromosome 3 at position 26.32 encodes the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha protein (also called p110α protein). It is a subunit of phosphatidylinositol 3-kinase (PI3K) and performs the action of PI3K, while the other subunit (produced by a different gene) regulates the enzyme's activity. PI3K phosphorylates certain signaling molecules that impact cell growth and division (proliferation), movement (migration) of cells, production of new proteins, transport of materials within cells, and cell survival. PI3K signaling may be involved in the regulation of several hormones and may play a role in the maturation of fat cells (adipocytes). Mutations in PIK3CA gene are associated with Klippel-Trenaunay syndrome, megalencephaly-capillary malformation syndrome (MCAP), bladder cancer and epidermal nevus.
PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung and other types of cancer. Cancer-associated PIK3CA gene mutations result in the production of an altered p110α subunit that allows PI3K to signal without regulation. The increased signaling can contribute to an uncontrolled proliferation of cells, leading to the development of cancer. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.
The Qiagen therascreen PIK3CA RGQ PCR assay is an FDA approved companion diagnostic test that enables qualitative detection of 11 mutations in the PIK3CA gene for in vitro diagnostic use. It is an FDA-approved CDx assay to identify patients with cases of breast cancer harboring actionable alterations for whom treatment with PIQRAY (alpelisib) may be appropriate.
- Identify breast cancer patients who may be eligible for treatment with PIQRAY(R) (alpelisib) based on a PIK3CA Mutation
- Identifying patient who may benefit from anti-EGFR therapy in metastatic colorectal cancer
- Diagnosis of Klippel-Trenaunay syndrome, megalencephaly-capillary malformation syndrome and many types of cancers such as bladder, breast, endometrial, colon and head and neck cancer
- For the clinical management and therapy of other cancers
- Mutation in PIK3CA might be used for selection and management of breast cancer treatment with PIQRAY(R) (alpelisib)
- PIK3CA mutation is likely to be predictive of a lack of benefit to anti-EGFR therapy in metastatic colorectal cancer.
- Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.
Negative for mutations analyzed (No pathogenic variant or mutation detected)
Formalin-fixed paraffin-embedded tissue blocks.
Stability
- Room temperature: indefinitely.
- Br J Cancer. 2006; 94: 455-459. [PMID: 16449998]
- J Pediatr. 2015;166: 1048-54.e1-5. [PMID: 25681199]
- Clin Colorectal Cancer. 2012;11: 143-50. [PMID: 22285706]
- Biochem Biophys Res Commun. 2009;381: 577-81. [PMID: 19233141]
- Nature. 2008;453: 662-6. [PMID: 18449193]
- Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/PIK3CA#
- GeneReviews® [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK153722/